Edition:
United Kingdom

Endocyte Inc (ECYT.OQ)

ECYT.OQ on NASDAQ Stock Exchange Global Select Market

9.33USD
26 Apr 2018
Change (% chg)

$0.30 (+3.32%)
Prev Close
$9.03
Open
$9.03
Day's High
$9.47
Day's Low
$8.95
Volume
162,945
Avg. Vol
453,922
52-wk High
$11.54
52-wk Low
$1.17

Latest Key Developments (Source: Significant Developments)

‍Partner Fund Management LP reports a 6.6 pct passive stake in Endocyte as of Nov 6
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - Endocyte Inc :‍Partner Fund Management LP reports a 6.6 percent passive stake in Endocyte Inc as of November 6 - SEC Filing​.  Full Article

Endocyte Q3 loss per share $0.55
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Endocyte Inc :Endocyte reports third quarter financial results.Q3 loss per share $0.55.  Full Article

Endocyte Inc files for mixed shelf of upto $150 million
Thursday, 12 Oct 2017 

Oct 12 (Reuters) - Endocyte Inc ::Endocyte Inc files for mixed shelf of upto $150 million .Endocyte Inc says in addition, selling stockholders may offer and sell, up to 5.3 million shares of co's common stock‍​.  Full Article

Peter Dodwell reports 7.1 pct passive stake in Endocyte Inc
Thursday, 12 Oct 2017 

Oct 12 (Reuters) - Endocyte Inc :Peter Dodwell reports 7.1 percent passive stake in Endocyte Inc ‍​as of September 29 - SEC filing.  Full Article

Endocyte reports Q2 loss per share $0.33
Thursday, 4 Aug 2016 

Endocyte Inc : Q2 loss per share $0.33 . Q2 earnings per share view $-0.26 -- Thomson Reuters I/B/E/S . Endocyte reports second quarter 2016 financial results .Company revised guidance for its expected cash balance at end of 2016 to be above $130 million.  Full Article

BRIEF-Endocyte Says Data Presented At AACR Show That EC17 Penetrates Solid Tumors Within Minutes And Is Retained Due To High Affinity For Folate Receptor

* ENDOCYTE INC - DATA PRESENTED AT AACR SHOW THAT EC17 PENETRATES SOLID TUMORS WITHIN MINUTES AND IS RETAINED DUE TO HIGH AFFINITY FOR FOLATE RECEPTOR Source text for Eikon: Further company coverage: